Formulation: A crystalline solid
Formal Name: N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-[(ethylamino)(ethylimino)methyl]-D-lysyl-L-leucyl-N6-[(ethylamino)(ethylimino)methyl]-L-lysyl-L-prolyl-D-alaninamide, diacetate
Purity: ≥98%
Formula Markup: C80H113ClN18O13 • 2C2H4O2
Formula Weight: 1690,4
Shelf life (days): 1460
CAS Number: 129311-55-3
Notes: Ganirelix is a gonadotropin-releasing hormone receptor (GNRHR) antagonist (IC50 = 3.6 nM; pA2 = 9.3).{39553} It induces a concentration-dependent increase in histamine release from rat peritoneal mast cells in vitro (EC50 = 11 μg/ml).{40810} In vivo, ganirelix (2 mg/kg, s.c.) decreases plasma testosterone in intact male rats for the first 7 days post-administration. Ganirelix (125 μg per day for 30 days) decreases the surface area of endometriotic lesions and serum progesterone levels in female baboons.{40811} Formulations containing ganirelix have been used to prevent premature ovulation in women undergoing in vitro fertilization.
English
Deutsch
